Novavax: Don't Catch The Falling Knives

264
38
Favorite

Novavax: Don't Catch The Falling Knives

Seeking Alpha2022-05-08

SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

264

Report

Comment（38）

XLMM
·2022-05-09
Here is a quick overview of the cases in US
Reply
Like
Report
XLMM
·2022-05-09
Well, it is definitely late to the party...but we are far from out from Covid. Look at the recentnumbers in US. NYC might bring back the westing mask mandate
Reply
1
Report
Cvt
·2022-05-09
A bit late
Reply
5
Report
nickg
·2022-05-09
🙏
Reply
2
Report
BennyTay
·2022-05-09
😅
Reply
1
Report
StarGalaxy
·2022-05-09
Ok
Reply
1
Report
EY12
·2022-05-09
Ok
Reply
1
Report
skyel
·2022-05-08
Perhaps to enlighten us on how to know the knife is still falling and when the knife reached the ground?
Reply
3
Report
Jjlim
·2022-05-08
👍🏻
Reply
2
Report
AhBart
·2022-05-08
Perhaps another new pandemic wave will save allthe vaccine makers 🤔
Reply
3
Report
Gaik11
·2022-05-08
Ok
Reply
2
Report
blessed_1
·2022-05-08
Thanks
Reply
3
Report
gotcha 99
·2022-05-08
Ok
Reply
3
Report
CIG
·2022-05-08
Usually seekingalpha = sell, but foxl = buy.
Reply
2
Report
SiniS
·2022-05-08
😊
Reply
4
Report
Vincentwong
·2022-05-08
Ok
Reply
3
Report
Lichiun
·2022-05-08
like pls, thank you!
Reply
5
Report
YS_ZENG
·2022-05-08
Like pls
Reply
3
Report
兔气扬眉
·2022-05-08
K
Reply
5
Report
ChunHui
·2022-05-08
Like
Reply
4
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1117562991?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-05-08 11:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117562991","market":"us","top_or_hot":-1,"title":"Novavax: Don't Catch The Falling Knives","media":"Seeking Alpha","content":"<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVAX","symbol_name":"诺瓦瓦克斯医药","start_time":0,"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","article_id":"1117562991","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","pubTimestamp":1651978981,"sourceInfo":null,"weMediaInfo":null,"summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"translate_title":"诺瓦瓦克斯：不要抓住掉落的刀","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVAX":0.9},"content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9062208975,"gmtCreate":1652059852897,"gmtModify":1676535021866,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://community-static.tradeup.com/news/5fd3a75ea7ccf88aca493e34c270e676","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":1,"crmLevelSwitch":0,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"htmlText":"Here is a quick overview of the cases in US&nbsp;","listText":"Here is a quick overview of the cases in US&nbsp;","text":"Here is a quick overview of the cases in US","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062208975","repostId":1117562991,"repostType":2,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062670345,"gmtCreate":1652059027687,"gmtModify":1676535021560,"author":{"id":"4100909250192760","authorId":"4100909250192760","name":"XLMM","avatar":"https://community-static.tradeup.com/news/5fd3a75ea7ccf88aca493e34c270e676","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":1,"crmLevelSwitch":0,"idStr":"4100909250192760","authorIdStr":"4100909250192760"},"htmlText":"Well, it is definitely late to the party...but we are far from out from Covid. Look at the recentnumbers in US. NYC might bring back the westing mask mandate&nbsp;","listText":"Well, it is definitely late to the party...but we are far from out from Covid. Look at the recentnumbers in US. NYC might bring back the westing mask mandate&nbsp;","text":"Well, it is definitely late to the party...but we are far from out from Covid. Look at the recentnumbers in US. NYC might bring back the westing mask mandate","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062670345","repostId":1117562991,"repostType":2,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062843830,"gmtCreate":1652053211720,"gmtModify":1676535018708,"author":{"id":"3579235597126488","authorId":"3579235597126488","name":"Cvt","avatar":"https://static.tigerbbs.com/c8fda02901ec7a98b51fe8e84d016ab2","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579235597126488","authorIdStr":"3579235597126488"},"htmlText":"A bit late","listText":"A bit late","text":"A bit late","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062843830","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062862681,"gmtCreate":1652051797943,"gmtModify":1676535018076,"author":{"id":"3582888334202818","authorId":"3582888334202818","name":"nickg","avatar":"https://static.tigerbbs.com/283279ba0e31ac4ba76eff1c33f18914","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3582888334202818","authorIdStr":"3582888334202818"},"htmlText":"🙏","listText":"🙏","text":"🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062862681","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062815267,"gmtCreate":1652050909559,"gmtModify":1676535017556,"author":{"id":"3578378737544841","authorId":"3578378737544841","name":"BennyTay","avatar":"https://community-static.tradeup.com/news/b2811d2536960cbba454a3f5f37fe4c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3578378737544841","authorIdStr":"3578378737544841"},"htmlText":"😅","listText":"😅","text":"😅","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062815267","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062813997,"gmtCreate":1652050565219,"gmtModify":1676535017439,"author":{"id":"4090381790893340","authorId":"4090381790893340","name":"StarGalaxy","avatar":"https://static.tigerbbs.com/49916fa198da24e2605abf24a28d23d2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4090381790893340","authorIdStr":"4090381790893340"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062813997","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062172549,"gmtCreate":1652047335181,"gmtModify":1676535016467,"author":{"id":"3569935580474431","authorId":"3569935580474431","name":"EY12","avatar":"https://static.tigerbbs.com/103e86782b34598ff73873d5f9259adb","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3569935580474431","authorIdStr":"3569935580474431"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062172549","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062188885,"gmtCreate":1652023368147,"gmtModify":1676535015143,"author":{"id":"3581505866102985","authorId":"3581505866102985","name":"skyel","avatar":"https://static.tigerbbs.com/a4e416c9b1fabad56fbe0e086388d5b0","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3581505866102985","authorIdStr":"3581505866102985"},"htmlText":"Perhaps to enlighten us on how to know the knife is still falling and when the knife reached the ground?&nbsp;","listText":"Perhaps to enlighten us on how to know the knife is still falling and when the knife reached the ground?&nbsp;","text":"Perhaps to enlighten us on how to know the knife is still falling and when the knife reached the ground?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062188885","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062130269,"gmtCreate":1652019938251,"gmtModify":1676535014555,"author":{"id":"3575345780958036","authorId":"3575345780958036","name":"Jjlim","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575345780958036","authorIdStr":"3575345780958036"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062130269","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062378190,"gmtCreate":1652015710011,"gmtModify":1676535013908,"author":{"id":"4099263395755910","authorId":"4099263395755910","name":"AhBart","avatar":"https://static.itradeup.com/news/5c8a0140b30f2d6c3be37b2ad1a1efe8","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4099263395755910","authorIdStr":"4099263395755910"},"htmlText":"Perhaps another new pandemic wave will save allthe vaccine makers 🤔","listText":"Perhaps another new pandemic wave will save allthe vaccine makers 🤔","text":"Perhaps another new pandemic wave will save allthe vaccine makers 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062378190","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062349277,"gmtCreate":1652013623599,"gmtModify":1676535013430,"author":{"id":"3578020712938440","authorId":"3578020712938440","name":"Gaik11","avatar":"https://community-static.tradeup.com/news/a0fd75ec6b06214ed80c93a51cd113db","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0,"idStr":"3578020712938440","authorIdStr":"3578020712938440"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062349277","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062938134,"gmtCreate":1651985003228,"gmtModify":1676535009268,"author":{"id":"4112410321254552","authorId":"4112410321254552","name":"blessed_1","avatar":"https://community-static.tradeup.com/news/71622697830d9517eb67a61917d8a95f","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":4,"crmLevelSwitch":1,"idStr":"4112410321254552","authorIdStr":"4112410321254552"},"htmlText":"Thanks&nbsp;","listText":"Thanks&nbsp;","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062938134","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062992923,"gmtCreate":1651983841262,"gmtModify":1676535009084,"author":{"id":"4111721294328662","authorId":"4111721294328662","name":"gotcha 99","avatar":"https://community-static.tradeup.com/news/473e69ae20d6102e460097704897f567","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4111721294328662","authorIdStr":"4111721294328662"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062992923","repostId":1117562991,"repostType":2,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062079763,"gmtCreate":1651981597252,"gmtModify":1676535008362,"author":{"id":"3583974841960176","authorId":"3583974841960176","name":"CIG","avatar":"https://static.tigerbbs.com/6c2077e2370e1ffcaca7e29b875be2be","vip":1,"hat":"https://static.tigerbbs.com/f84d87792f02cf78e80ee34979fd31e5","crmLevel":5,"crmLevelSwitch":1,"idStr":"3583974841960176","authorIdStr":"3583974841960176"},"htmlText":"Usually seekingalpha = sell, but foxl&nbsp;= buy.","listText":"Usually seekingalpha = sell, but foxl&nbsp;= buy.","text":"Usually seekingalpha = sell, but foxl = buy.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062079763","repostId":1117562991,"repostType":2,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062056726,"gmtCreate":1651980082265,"gmtModify":1676535007903,"author":{"id":"3575200115109066","authorId":"3575200115109066","name":"SiniS","avatar":"https://static.tigerbbs.com/6c54fb65b275549d9e3c4b80c5117022","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3575200115109066","authorIdStr":"3575200115109066"},"htmlText":"😊","listText":"😊","text":"😊","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062056726","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062051218,"gmtCreate":1651979677834,"gmtModify":1676535007846,"author":{"id":"4088590202250050","authorId":"4088590202250050","name":"Vincentwong","avatar":"https://community-static.tradeup.com/news/d33ac9d4da6230b64c0a0c9b3b75281e","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088590202250050","authorIdStr":"4088590202250050"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062051218","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062053368,"gmtCreate":1651979584154,"gmtModify":1676535007855,"author":{"id":"3568372592076919","authorId":"3568372592076919","name":"Lichiun","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3568372592076919","authorIdStr":"3568372592076919"},"htmlText":"like pls, thank you!","listText":"like pls, thank you!","text":"like pls, thank you!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062053368","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062059759,"gmtCreate":1651979531171,"gmtModify":1676535007815,"author":{"id":"3561416218644754","authorId":"3561416218644754","name":"YS_ZENG","avatar":"https://static.tigerbbs.com/80872255ccfe73879d5d778410465550","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"3561416218644754","authorIdStr":"3561416218644754"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062059759","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062059493,"gmtCreate":1651979526412,"gmtModify":1676535007802,"author":{"id":"3568026014768326","authorId":"3568026014768326","name":"兔气扬眉","avatar":"https://community-static.tradeup.com/news/58fe9e54c89b636f385d436c63c3e4f2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3568026014768326","authorIdStr":"3568026014768326"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062059493","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9062059565,"gmtCreate":1651979523557,"gmtModify":1676535007800,"author":{"id":"3581852672614632","authorId":"3581852672614632","name":"ChunHui","avatar":"https://static.tigerbbs.com/bc47341688d5ff26c7994db9a3a6f6ac","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0,"idStr":"3581852672614632","authorIdStr":"3581852672614632"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9062059565","repostId":1117562991,"repostType":4,"repost":{"id":"1117562991","kind":"news","pubTimestamp":1651978981,"share":"https://ttm.financial/m/news/1117562991?lang=&edition=fundamental","pubTime":"2022-05-08 11:03","market":"us","language":"en","title":"Novavax: Don't Catch The Falling Knives","url":"https://stock-news.laohu8.com/highlight/detail?id=1117562991","media":"Seeking Alpha","summary":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the ","content":"<html><head></head><body><p>Summary</p><ul><li>Novavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.</li><li>Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.</li><li>Therefore, we revise our rating on NVAX stock from Buy to Sell. Don&#39;t catch the falling knives from here.</li></ul><p>Investment Thesis</p><p>Novavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.</p><p>In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted &#34;if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.&#34;</p><p>Furthermore, Novavax&#39;s key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that &#34;supply outpaced demand amid global vaccine glut.&#34;</p><p>As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.</p><p>Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.</p><p>As a result, we revise our rating on NVAX stock from Buy to Sell.</p><p>NVAX Stock Deserves Its Lower Valuation Multiples<img src=\"https://static.tigerbbs.com/03a4e51160f8b018f1c769d47982b446\" tg-width=\"640\" tg-height=\"384\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock NTM revenue multiples(TIKR)</p><p>NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers&#39; vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.</p><p>While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax&#39;s vaccine holds tremendous promise, it&#39;s simply too little too late.</p><p>Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these &#34;lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.&#34; As a result, &#34;the vaccine landscape has changed drastically in recent months.&#34;</p><p>Notably, Pfizer (PFE) also declined to provide an update on FY23&#39;s visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax&#39;s estimates for FY22-23 could have significant downside risks.</p><p>Novavax&#39;s Estimates Revised Downwards<img src=\"https://static.tigerbbs.com/fc50807c7a93b44fec42a8bb17d30faf\" tg-width=\"640\" tg-height=\"395\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>Novavax revenue consensus estimates(S&amp;P Capital IQ)</p><p>Hence, investors shouldn&#39;t be surprised that Novavax&#39;s revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March&#39;s estimates of $909.08M. However, the Street remains convinced that Novavax&#39;s revenue growth could gain momentum from Q2. Therefore, we believe that it&#39;s imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.</p><p>Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.</p><p>Is NVAX Stock A Buy, Sell, Or Hold?<img src=\"https://static.tigerbbs.com/1fe89d7d4e0995b3b31ef612aa3733da\" tg-width=\"640\" tg-height=\"356\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"/></p><p>NVAX stock price chart(TradingView)</p><p>The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.</p><p>Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we <i>revise our rating on NVAX stock from Buy to Sell</i>ahead of its Q1 card.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax: Don't Catch The Falling Knives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax: Don't Catch The Falling Knives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-05-08 11:03 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax ...</p>\n\n<a href=\"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/article/4508330-novavax-falling-knive-stock-sell","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117562991","content_text":"SummaryNovavax is scheduled to report its Q1 earnings on May 9. Unfortunately, the situation in the COVID-19 vaccines market has changed significantly. Now, we have an oversupply reality.Yet, Novavax still does not have its EUA from the US FDA. Also, we think its revenue visibility for FY22-23 is at risk.Therefore, we revise our rating on NVAX stock from Buy to Sell. Don't catch the falling knives from here.Investment ThesisNovavax, Inc. (NASDAQ:NVAX) is slated to report its Q1 earnings on May 9, ahead of the FDA review of its EUAfor its COVID-19 vaccine. As a result, Novavax investors have been waiting for a considerable amount of time. Unfortunately, much has changed over the last few months since its FQ4 earnings call.In April, Moderna (MRNA) highlighted that the world now has an oversupply of COVID-19 vaccines. It also added that COVAX declined to take up additional options for more vaccines. In its Q1 earnings call, it also highlighted that its FY22 COVID-19 vaccines guidance could be impacted \"if COVAX is unable to confirm demand aligned to their contracted volume in the 2022 calendar year.\"Furthermore, Novavax's key manufacturing partner Serum Institute of India, reportedly suspended the production of COVID-19 vaccines back in December 2021. It highlighted that \"supply outpaced demand amid global vaccine glut.\"As a result, NVAX stock investors should not be surprised that its stock has collapsed 83% from its 2021 highs. We were cautiously optimistic in a previous update, as it had managed to gain several EUAs outside of the US. However, we think the tide has turned significantly for Novavax.Despite the significant battering in its price, we think the time has come for Novavax investors to use any rally in NVAX stock to cut exposure partially or fully.As a result, we revise our rating on NVAX stock from Buy to Sell.NVAX Stock Deserves Its Lower Valuation MultiplesNVAX stock NTM revenue multiples(TIKR)NVAX stock last traded at an NTM revenue multiple of 0.8x. It was well below the valuations of its two leading mRNA counterparts, Moderna and BioNTech (BNTX) stock. We think the bifurcation is justified, given the proven commercial success of its mRNA peers' vaccines. Furthermore, they have several pipelines developed on top of their proven mRNA platforms that should attract more confidence from biotech investors.While Novavax keeps its investors on tenterhooks, Moderna and BioNTech have capitalized on its tardiness and dominated the COVID-19 vaccines market. So even though we recognized that Novavax's vaccine holds tremendous promise, it's simply too little too late.Furthermore, the reality in The African Union and COVAX accentuated the waning demand for COVID-19 vaccines as they dealt with several challenges. Bloomberg reported that these \"lower-income countries left behind in the global rollout are now grappling with a lack of funds, hesitancy, supply-chain obstacles, and other factors that are hampering distribution.\" As a result, \"the vaccine landscape has changed drastically in recent months.\"Notably, Pfizer (PFE) also declined to provide an update on FY23's visibility, despite reiterating its guidance for 2022. Therefore, we believe that the oversupply situation in 2022 would likely drag on further to 2023. As a result, Novavax's estimates for FY22-23 could have significant downside risks.Novavax's Estimates Revised DownwardsNovavax revenue consensus estimates(S&P Capital IQ)Hence, investors shouldn't be surprised that Novavax's revenue estimates have been revised downwards to reflect these uncertainties. The updated consensus estimates suggest the revenue bar that Novavax needs to clear in Q1 is $845.2M, down from March's estimates of $909.08M. However, the Street remains convinced that Novavax's revenue growth could gain momentum from Q2. Therefore, we believe that it's imperative for Novavax to reiterate or raise its previous FY22 guidance of $4.5B to assuage the market.Nevertheless, we believe that the market remains uncertain over its guidance from FY23. As a result, we think the lack of visibility from its mRNA counterparts could continue to hamper NVAX stock momentum moving forward. Moreover, we believe it will be a tall order for management to communicate guidance beyond FY22, given the dynamics in the supply situation surrounding the COVID-19 vaccines.Is NVAX Stock A Buy, Sell, Or Hold?NVAX stock price chart(TradingView)The bull trap in early 2021 proved prescient for investors who sold into that rally and took profit astutely. NVAX stock bagholders are now left with a mess as it broke below a critical support zone ($76) in April 2022. A recovery above that zone will be critical for NVAX stock to regain its support. Otherwise, it is increasingly likely that the stock is currently in free fall to an undetermined support level.Therefore, we think the speculative run on NVAX stock has come to an abrupt end. Accordingly, we revise our rating on NVAX stock from Buy to Sellahead of its Q1 card.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":264,"commentSize":38,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}